Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Aza-Blanc

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Oncogene|November 2, 2004
RNAi and HTS: exploring cancer by systematic loss-of-functionAarron T Willingham, Quinn L Deveraux, Garret M Hampton, et al.
Journal of Virology|January 15, 2010
Identification of host factors involved in borna disease virus cell entry through a small interfering RNA functional genetic screenRoberto Clemente, Eugene Sisman, Pedro Aza-Blanc, et al.
Plos One|March 20, 2015
PCTAIRE1-knockdown sensitizes cancer cells to TNF family cytokinesTeruki Yanagi, Ranxin Shi, Pedro Aza-Blanc, et al.
The Journal of Biological Chemistry|February 27, 2019
Withdrawal: <i>Dm1</i>-MMP, a matrix metalloproteinase from <i>Drosophila</i> with a potential role in extracellular matrix remodeling during neural developmentElena Llano, Alberto M Pendás, Pedro Aza-Blanc, et al.
Molecular Cell|October 7, 2003
Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screeningPedro Aza-Blanc, Christopher L Cooper, Klaus Wagner, et al.
Methods (San Diego, Calif.)|May 29, 2007
PTPome-wide functional RNA interference screening methodsAmanda M Opaluch, Pedro Aza-Blanc, Torkel Vang, et al.
Molecular Biology of the Cell|September 10, 2004
Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particleYan-Guo Ren, Klaus W Wagner, Deborah A Knee, et al.
Seminars in Cancer Biology|October 18, 2003
Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAiQuinn L Deveraux, Pedro Aza-Blanc, Klaus W Wagner, et al.
Oncotarget|March 10, 2015
Glutamate and asparagine cataplerosis underlie glutamine addiction in melanomaBoris Ratnikov, Pedro Aza-Blanc, Ze'ev A Ronai, et al.
Cancer Research|October 5, 2016
miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3Ying Zhou, Jason Dang, Kung-Yen Chang, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Oncogene|November 2, 2004
RNAi and HTS: exploring cancer by systematic loss-of-functionAarron T Willingham, Quinn L Deveraux, Garret M Hampton, et al.
Journal of Virology|January 15, 2010
Identification of host factors involved in borna disease virus cell entry through a small interfering RNA functional genetic screenRoberto Clemente, Eugene Sisman, Pedro Aza-Blanc, et al.
Plos One|March 20, 2015
PCTAIRE1-knockdown sensitizes cancer cells to TNF family cytokinesTeruki Yanagi, Ranxin Shi, Pedro Aza-Blanc, et al.
The Journal of Biological Chemistry|February 27, 2019
Withdrawal: <i>Dm1</i>-MMP, a matrix metalloproteinase from <i>Drosophila</i> with a potential role in extracellular matrix remodeling during neural developmentElena Llano, Alberto M Pendás, Pedro Aza-Blanc, et al.
Molecular Cell|October 7, 2003
Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screeningPedro Aza-Blanc, Christopher L Cooper, Klaus Wagner, et al.
Methods (San Diego, Calif.)|May 29, 2007
PTPome-wide functional RNA interference screening methodsAmanda M Opaluch, Pedro Aza-Blanc, Torkel Vang, et al.
Molecular Biology of the Cell|September 10, 2004
Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particleYan-Guo Ren, Klaus W Wagner, Deborah A Knee, et al.
Seminars in Cancer Biology|October 18, 2003
Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAiQuinn L Deveraux, Pedro Aza-Blanc, Klaus W Wagner, et al.
Oncotarget|March 10, 2015
Glutamate and asparagine cataplerosis underlie glutamine addiction in melanomaBoris Ratnikov, Pedro Aza-Blanc, Ze'ev A Ronai, et al.
Cancer Research|October 5, 2016
miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3Ying Zhou, Jason Dang, Kung-Yen Chang, et al.
Pageof 4